相关实验视频

Updated: Jul 5, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

在CABG后早期使用萨库比特里尔/瓦尔沙坦

Madina Nurzhanova^1,2, Aisulu Musagaliyeva¹, Raushan Zhakypova¹

¹Scientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan.

|January 18, 2024

概括

在冠状动脉旁路移植 (CABG) 后在心力衰竭患者中早期启动sacubitril/valsartan是安全有效的. 这种方法显著降低了NT-proBNP水平,改善了生活质量和运动能力.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
临床医学临床医学

背景情况:

心力衰竭 (HF) 显著影响全球公共卫生.
冠状动脉旁路移植 (CABG) 可能会改善缺血性心肌病的存活率,但会带来风险.
对HF患者的最佳复血管化策略仍在研究中.

研究的目的:

评估在CABG后的稳定HF患者中早期启动sacubitril/valsartan的安全性和有效性.
评估不良事件,生活质量,NT-proBNP水平和6分钟步行测试 (6MWT) 的表现.

主要方法:

在CABG后,对大约80名HFrEF患者进行了开放式随机研究.
随机分配到早期或晚期启动萨库比特里尔/瓦尔萨坦的患者.
主要终点:安全结果. 二级终点:生活质量,NT-proBNP和6MWT.

主要成果:

招募了77名患者;停药率低 (2.5-5.2%).
两组之间功能,高血或低血压没有显著差异.
显著改善生活质量和6MWT距离 (p<0.001).
NT-proBNP水平显著下降,特别是在早期启动组 (p<0.001).

结论:

在CABG后的HFrEF患者中,早期启动sacubitril/valsartan是安全有效的.
观察到不良事件的低发病率和永久停药.
在NT-proBNP水平的显著降低支持早期入院启动.

关键词:

冠状动脉绕道 (bypass) 是一种冠状动脉绕道.冠状动脉疾病冠状动脉疾病这是心脏衰竭.药理学,临床药理学

更多相关视频

Implantation of the Syncardia Total Artificial Heart

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...